{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069301","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.118547+00:00","generated_at":"2026-05-22T00:55:01.386371+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Perspective Therapeutics Q1 net loss $18.2M; VMT-α-NET cohort enrollment reaches 40 patients","bullets":["Net loss $18.2M ($0.25 loss per share) vs $12.3M loss in prior year; R&D spend +92% to $14.3M.","Cash $212M as of March 31; expects funding into late 2026; sold $10.2M in ATM shares in Feb 2025 at ~$3.02/share.","VMT-α-NET: 40 patients enrolled in Cohort 2 as of April 30; data accepted for oral ASCO 2025 presentation.","VMT01: first patient treated at new monotherapy dose level (April 2025) and in combo with nivolumab (March 2025).","PSV359: first patient dosed; three new U.S. manufacturing sites underway for future commercial demand."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069301","json":"https://secwatch.observer/filing/0000950170-25-069301.json","markdown":"https://secwatch.observer/filing/0000950170-25-069301.md","text":"https://secwatch.observer/filing/0000950170-25-069301.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017025069301/0000950170-25-069301-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017025069301/catx-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:55:01.386371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}